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EFFECTIVENESS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
MANAGEMENT PROGRAM AT THE UNIVERSITY OF LOUISVILLE 





Background: Chronic obstructive pulmonary disease (COPD) is a progressive disease of 
the respiratory system characterized by airflow limitation that is not completely 
reversible and is associated with systemic effects especially of the cardiovascular system.  
COPD is frequently complicated by acute exacerbations that contribute to physical 
impairment and increased health care use.  As COPD is a chronic lung disease with 
significant systemic manifestations, it is important to have chronic disease management 
programs specifically targeting individuals with COPD designed to improve their overall 
quality of life, reduce the burden of disease and decrease the impact of COPD on daily 
life.  Chronic disease management encompasses a multidisciplinary approach designed to 
enhance the quality and cost-effectiveness of health care for chronic conditions
 
and has 
been defined as “an approach to patient care that emphasizes coordinated, comprehensive 
care along the continuum of disease and across health care delivery systems”.  The 




pulmonary disease management program implemented at the University of Louisville in 
2011. 
Methods: We conducted a retrospective observational cohort study of COPD subjects 
using clinical data from medical records and cost data from a claims dataset.  Respiratory 
health was assessed by pulmonary function testing, St. George Respiratory questionnaire, 
COPD Assessment Test (CAT), 6 minute walk test (6MWT), Modified Medical Research 
Council (mMRC) dyspnea scale, and BODE index.  General measures include Duke 
Profile for assessing overall health and Patient Health Questionnaire (PHQ-9) for 
assessing depression.  At baseline, chi-square test for categorical variable and t-test for 
continuous variable was used to check for any difference between the two groups.  To 
check for any longitudinal significant change in quality of life measures like SGRQ, CAT 
score, mMRC scale, BODE index, six minute walk distance and PFT measures from 
baseline paired t-test was performed.  For each subject, the baseline probability of 
participation in the disease management program was calculated by the propensity score 
method using logistic regression analysis.  Multiple linear regression analysis was 
performed to assess the rate of deterioration of various clinical parameters like FEV1 and 
FVC between two groups.  Cost analysis was done by comparing the cost related to 
COPD among subjects in DMP group versus those under usual care.  These costs 
includes total COPD cost, and also sub-categories of cost like office visit cost, in-patient 
hospitalization (IPH) cost, out-patient hospitalization (OPH) cost, pharmacy cost, cost 
related to home care and laboratory cost. 
Results:  A total of 52 subjects were enrolled in the disease management program 
between February 1
st
 2011 and December 31
st
 2013: 37 in 2011, 11 in 2012 and 4 in 
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2013.  The usual care group consists of 662 subjects diagnosed with COPD.  There is a 
significant difference in average age of subjects between the two groups (54.2 in DMP 
versus 58.3 in usual care; P value 0.0094).  Subjects who suffered from asthma, rhinitis 
and arthritis were significantly more likely to enroll in the disease management program.  
At baseline, the average PHQ9 was 6.3 which improved at the end of 12 months (mean = 
4) and at 24 months (mean = 3.1).  At baseline, the average duke score was 64.1 which 
were improved at the end of 12 months (mean = 71.6) and 24 months (mean = 68.3).  At 
baseline average SGRQ score was 37.1 which were improved at the end of 12 months 
(mean = 28.4, P = 0.02) and 24 months from (mean = 30.2, P = 0.21).  We found that not 
only did those subjects enrolled in the COPD program decrease their rate of loss of lung 
function, but remarkably showed a significant improvement in FEV1 from baseline to 12 
months (mean difference: 140 ml, P value = 0.0046) and from baseline to 24 months 
(mean difference: 30 ml, P value 0.55).  Average cost per person per year among subjects 
in DMP group in first year is $3693, which decreased to $3608.8 in second year and to 
$2934 in third year.  Pharmacy cost contributes majority of total COPD cost followed by 
office cost and out-patient hospitalization.  There is a significant decline in cost related to 
all major diseases like arthritis, hypertension, hyperlipidemia, diabetes, and osteoporosis 
after enrollment of COPD subjects into disease management program comparing to cost 
before enrollment into program.  Average cost per person per year for in-patient 
hospitalization is significantly high for subjects in usual care ($5578.7) versus subjects in 
DMP group ($250.9). 
Conclusion:  The University of Louisville COPD disease management program appears 
to be effective in improving lung health and reducing airflow limitations among COPD 
ix 
 
subjects as evidence by significant improvement in objective measures like FEV1.  
Program is also effective in reducing the impact of COPD on daily activities as evident 
by significant improvement in subjective measures for health related quality of life like St 
George Respiratory Questionnaire, COPD assessment test, PHQ9 and Duke Profile.  
Notwithstanding subjects in DMP had higher COPD related cost, they had significantly 
low in-patient hospitalization cost and also significant reduction in cost associated with 
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Chronic obstructive pulmonary disease (COPD) is a progressive disease of the 
respiratory system characterized by airflow limitation that is not completely reversible 
and is associated with systemic effects especially of the cardiovascular system
1,2
.  COPD 
is frequently complicated by acute exacerbations that contribute to physical impairment 
and increased health care use
2
.  The COPD GOLD (Global Initiative for Obstructive 
Lung Disease) stage directly correlates with both severity and frequency of acute 
exacerbations
3
.  COPD is a major public health burden whose current prevalence is 
estimated to be approximately 8-10% in adults aged 40 years or more in developed 
countries like the USA.  However, in developing countries, the prevalence varies widely 
and is difficult to estimate because of different definitions used to identify cases of 
COPD
4
.  Regardless of the burden that COPD places on health care systems and the 
availability of recommendations for its management
1
, COPD remains a condition that is 
all too often sub-optimally managed.  As COPD is a chronic lung disease with significant 
systemic manifestations, it is important to have chronic disease management programs 
specifically targeting individuals with COPD designed to improve their overall quality of 
life, reduce the burden of disease and decrease the impact of COPD on daily life.  The 
University of Louisville implemented a chronic disease management program (DMP) for 
COPD in 2011.  We evaluate here the clinical and cost effectiveness of the DMP for 




Definition of COPD 
COPD is a disease characterized by the combination of two conditions: chronic 
bronchitis and pulmonary emphysema
5,6
.  Chronic bronchitis is best characterized as 
chronic inflammation of the bronchial airways and is defined clinically “as cough with 
sputum production every day for at least three months in a year for two or more 
consecutive years”
7,8
.  Pulmonary emphysema, on the other hand, is defined 
pathologically as “a dilation of alveoli distal to the terminal bronchioles along with 
destruction of the lining of the air sacs”
6
.  There are many ways of defining COPD but 
the widely accepted definitions of COPD are from the American Thoracic Society (ATS), 
the European Respiratory Society (ERS) and the Global Initiative for chronic Obstructive 
Lung Disease (GOLD).   
According to the ATS definition
9
 COPD is  “a disease state characterized by the 
presence of airflow limitation due to chronic bronchitis or emphysema; the airflow 
obstruction is generally progressive, may be accompanied by airway hyperreactivity, and 
may be partially reversible”.  As per ERS, COPD is defined as 
10
 “reduced maximum 
expiratory flow and slow forced emptying of the lungs, which is slowly progressive and 
mostly irreversible to present medical treatment”.  GOLD defines COPD as 
11
  “a disease 
state characterized by airflow limitation that is not fully reversible and the airway 




“a preventable and treatable disease state characterized by airflow limitation that is not 
fully reversible” and is the most common definition being used now
1
.  COPD is classified 
into four stages based on FEV1/FVC ratio and % predicted FEV1.  In all four stages 
FEV1/FVC ratio is <0.7 and severity is further classified based on % predicted FEV1.  In 
Stage 1 (mild) % predicted FEV1 is ≥ 80, Stage-II (moderate) it is 50-79 , Stage III 
(severe) it is 30-49 and Stage IV (very severe) it is ≤ 30
11
.  The prevalence of COPD 





Spirometry   
Spirometry is a routinely performed pulmonary function test
13
 and, as the name 
suggests, is a measurement of the amount of air you breathe.  This includes 
measurements of both the volume and rate of air that can be inhaled and exhaled as a 




 publish guidelines for performing and 
interpreting pulmonary function tests in respiratory diseases like COPD and Asthma.  
Based on spirometry testing results, patient can be classified further into an obstructive or 
restrictive pattern of pulmonary disease (See Table 1). 
Important spirometry measurements of the pulmonary function test
16
 are forced 
vital capacity (FVC), forced expiratory volume (FEV), peak expiratory flow (PEF), 
maximum voluntary ventilation (MVV), total lung capacity (TLC), functional residual 
capacity (FRC), and residual volume (RV)
16
.  FVC is the maximum volume of air 
exhaled forcefully following a maximal inspiratory effort.  FEV is the volume of air 
4 
 
exhaled with force in one breath.  The volume of air exhaled measured after 1 second is 
called the FEV1.  FEV1 is one of the important spirometry measures in COPD subjects.  
PEF measures how quickly one can exhale and is the highest airflow rate measured 
during the FVC procedure.  MVV is the greatest amount of air that one can breathe in and 
out during a one minute interval.  TLC is the amount of air contained in the lungs after a 
full inspiration.  FRC is the amount of air in lungs at the end of a normal exhaled breath.  
Residual volume is the amount of air remained in lungs after full expiration.  
 The primary pulmonary function parameters that distinguish obstructive versus 
restrictive lung disease are FEV1, FVC and the ratio of FEV1 to FVC expressed as a 
percentage (FEV1/FVC %).  Table 1 summarizes the different findings of pulmonary 
function tests in individuals who are normal and those with obstructive lung disease and 
restrictive lung disease
17
.  The rates of decline of FEV1 with age in different ethnic 
groups are shown in Appendix 1 and 2. 
Table 1 Pulmonary Function test findings in different lung disease 
 




% predicted FEV1 Normal (80-120%) Low Low 
% predicted FVC Normal (80-120%) Low or normal Low 







Spirometry measurements in NHANES 
National Health and Nutritional Examination Survey (NHANES) is a series of 
complex surveys started in 1960 to assess the health and nutritional status of adults and 
children in USA
18
.  The survey includes history, personal interview and physical exam of 
the participant.  Spirometry was done in NHANES with a primary focus to assess the 
burden of respiratory diseases, like asthma and COPD, among the US general population 
and also to calculate estimated prevalence of COPD.  NHANES III data was used to 
calculate reference standards for spirometry
19
.  NHANES III was a stratified multistage 
probability sample of the U.S. population and the survey was conducted nationally by the 
National Center for Health Statistics (NCHS) from 1988 to 1994
20
.  Hankinson (1999)
19
 
conducted a detailed analysis of NHANES III spirometry data to generate reference 
equations for describing pulmonary function in three major ethnic groups namely 
Caucasians, African-Americans and Mexican-Americans.  Comparing FEV1 against age 
for different ethnic groups (See Appendix 1) it can be seen that both Mexican-Americans 
and African-Americans, irrespective of gender, have lower FEV1 values than do 
Caucasians for all age groups
19
.  Whereas comparing FEV1 against height, only African-
Americans had lower FEV1 values while Caucasians and Mexican-Americans had similar 
values
19
.  Along with absolute FEV1 and FVC values, % predicted values are calculated 
by comparing the values of similar age, gender and body composition.  NHANES III 







The rate of decline of FEV1 by age is directly related to the severity of airway 
inflammation
13





, and COPD prognosis
2
.  COPD patients 




The Spirometry Longitudinal data Analysis (SPIROLA) software designed and 
developed by CDC has been used to estimate the decline in slope of pulmonary function 
(e.g. FEV1) and can be used to compare to a normal decline in people of the same age, 
gender and height
23
.  SPIROLA software uses the NHANES III standard developed by 
Hankinson et. al. in 1999 to calculate the slope and compare it to normal individuals.  
This software is being widely used in workplace settings to monitor FEV1 and FVC 
longitudinally over time among occupational workers
24
.  Longitudinal monitoring in the 
work place settings is very important for the identification of individuals who are at high 
risk of developing COPD based on their excessive loss of lung function
24
.  SPIROLA 
will be useful in this setting by allowing for the implementation of proper treatment or 
prevention strategies for high risk workers that may delay or reduce the loss of lung 
function.  SPIROLA can perform individual or group evaluation of longitudinal changes 
in pulmonary function.  At the individual level it can monitor FEV1 change over time in 
relation to the limit of longitudinal decline (LLD).  It can be downloaded free from 







Pathophysiology of COPD 
 
COPD is a disease characterized by airflow limitation which is poorly reversible.  
The basic pathogenesis occurring in COPD patients involves damage to lung tissue due to 
chronic inflammation aggravated by smoking and other toxins
25
.  The detailed 
pathophysiology of COPD has been discussed in many articles
25-28
.  Exposure to airway 
irritants causes accumulation of inflammatory cells, including neutrophils, lymphocytes 
and macrophages and initiates the release of various inflammatory mediators such as 
tumor necrosis factor, C - reactive protein, and interleukins resulting in structural damage 
to lung parenchyma
14
.  A detailed role of chronic inflammation was studied by Denterer 
et. al. with the aim to test the hypothesis that chronic inflammation in COPD is due to 
defective anti-inflammatory mechanism(s).  This study concluded that in patients with 
stable COPD, there is a significantly higher level of leukocyte counts, C-reactive protein 
(CRP), and lipopolysaccharide binding protein (LBP).  They showed that effective COPD 
treatment significantly reduces levels of CRP and LBP in comparison to baseline levels
28
.  
Apart from inflammation, other pathological factors involved in COPD include 
increased levels of proteases
27
, decreased levels of anti-proteases and oxidative stress.  
The above pathogenic mechanisms leads to a series of physiological abnormalities in 
COPD including airflow obstruction due to mucosal hyper-secretion and mucosal edema, 
airway hyperresponsiveness, hyperinflation of lung, dysfunction of cilia, loss of elasticity 







Natural history of COPD 
 
 As discussed in the above definitions, COPD is a chronic progressive disease with 
airway limitation not completely reversible.  The most important parameter that measures 
airflow limitation is FEV1.  Hence the natural history of the disease strongly correlates 
with the level of FEV1 from birth.  Appendix 2 displays the normal decline of FEV1 by 
age (Curve D) alongside impaired lung growth (Curve A), early decline (Curve B) and 
rapid decline (Curve C)
29
.  Subject A has impaired lung growth with a lower plateau 
phase but the rate of decline in FEV1 is normal.  Subject B has normal lung growth (i.e. 
normal plateau) and a rapid decline in initial years but the rate of decline is normal 
thereafter.  Subject C has a normal plateau and normal decline in initial years but the rate 
of decline accelerates thereafter.  Most published literature uses FEV1 to study the natural 
history of disease
29-31
; but if someone starts smoking very early they could just skip the 
plateau phase and proceed directly to rapid decline after early lung growth
32
.  Gold. et. al. 
conducted a detailed study of tobacco smoke effects on adolescent boys and girls
32
.  The 
study found that girls who smoke 5 or more cigarettes per day have 1.09% (95% CI: 0.7-
1.47) slower growth of FEV1 per year versus non-smokers and 0.2% slower growth 
among boys who smokes versus non-smokers (95% CI: -0.16 to 0.56).  In a detailed 
review of the pathophysiology and natural history of disease by Mannino et. al.
33,34
, the 
author’s state that FEV1 is not the only parameter of interest in the natural history of 
COPD.  Since COPD is a heterogeneous disease, it should be noted that the natural 
history of COPD is a mixture of naturally occurring phenotypes including small airway 






Pharmacotherapy of COPD 
 
 Apart from monitoring the disease and reducing risk factors, effective 
management of COPD includes management of stable COPD and also exacerbations 
which requires proper use of drugs
11
.  The principal role of drugs in COPD treatment is to 
improve the symptoms, reduce frequency of exacerbations, reduce severity of disease, 
slow the progression of disease and improve the quality of life
11
.  The primary categories 




.  These can 
be given alone or in combination therapy and either inhaled or in oral form
35




 Any medication that dilates bronchi and bronchioles, by altering the tone of 
airway smooth muscle, is called a bronchodilator.  Bronchodilators also improve FEV1 
and other parameters like forced vital capacity and residual volume.  There are three 
types of bronchodilators commonly given to COPD subjects.  These include β adrenergic 
receptor agonists, anti-cholinergic agents and methyxanthines
36
.  A β2 adrenergic receptor 
agonist relaxes airway smooth muscle by stimulating β2 receptors present on respiratory 
airways resulting in increases in intracellular levels of cyclic adenosine monophosphate 
(c-AMP)
37
.  β2 agonists are either short acting (SABA) or long acting (LABA).  SABA 
effects last for 4-6 hours and LABA have duration of effect lasting for up to 12 hours.  
The most common side effects of β2 agonist bronchodilators include tremor, tachycardia, 
anxiety, nervousness and headache
38
.  Anti-cholinergic drugs relax smooth muscle by 
blocking the action of acetylcholine on M3 and M2 receptors.  The most common side 
effects of anti-cholinergic drugs include constipation, dryness of skin due to decreased 
10 
 
sweating, dryness of mouth, headache, and blurring of vision.  The last group of 
bronchodilators is the methyxanthines which dilate bronchioles by acting as non-selective 
phosphodiesterase inhibitors.  The most common drug in this category is theophylline 
which has been used as a bronchodilator for over 80 years.  Theophylline is not 





 Steroids can be given either orally (OCS) or inhaled (ICS)
40
.  In contrast to 
asthma, subjects with COPD are less responsive to inhaled corticosteroids (ICS) if given 
alone and so ICS are given in combination with bronchodilators
40,41
.  Inhaled 
corticosteroids given in combination with bronchodilators reduce acute COPD 
exacerbations and improve overall quality of life
42,43
.  Anuzeto conducted a randomized 
clinical trial comparing the effect of fluticasone propionate (ICS) given in combination 
with salmeterol versus salmeterol alone and found that there was a significant reduction 
in moderate to severe acute exacerbations in the combination arm (1.1 vs. 1.50 per 
subject per year) along with fewer hospitalizations than in the salmeterol alone arm
44
.  
Several other studies support the use of inhaled corticosteroids to improve outcomes and 
reduce exacerbations among COPD subjects
45,46
.  Common side effects of oral steroids 
include weight gain, mood changes, increase in blood sugar, increase in blood pressure, 
and osteoporosis (if used for long term).  Side effects associated with inhaled steroids are 







Epidemiology of COPD   
 
COPD is a leading cause of morbidity and mortality not only in the USA but also 
globally
4,47
.  Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic 
morbidity and a public health problem of increasing concern in the United States
12,48
.  
According to World Health Organization (WHO), the estimated prevalence of moderate 
to severe COPD is 65 million and  COPD is the fourth leading cause of mortality (3.4 
million) worldwide after ischemic heart disease (7 million), stroke (6.2 million) and 




Prevalence of COPD 
The prevalence of COPD varies depending on the definition and type of survey 
used to estimate its prevalence.  The first national survey to estimate the prevalence of 
COPD was NHIS (National Health Interview Survey)
50
.  In that survey, COPD 
prevalence was estimated by adding the cases of chronic bronchitis (50.5 per 1000 
persons for all age) and emphysema (6.0 per 1000 persons for all age)
51
.  Accordingly, 
the NHIS survey calculated that there were approximately 12.7 million adults above 25 
years of age living with COPD.  Unfortunately, COPD is under diagnosed as the 
diagnosis is based on self-report to two questions
12
.  Due to this limitation, Mannino et. 
al. used pulmonary function test measures from the NHANES-III survey to estimate the 
prevalence of COPD
12
.  NHANES-III used a stratified, clustered design to select a 
representative sample of the civilian, non-institutionalized USA population from 1988 to 
1994 and it included pulmonary function testing
52
.  Prevalence was estimated by applying 
GOLD stage criteria to pulmonary function test measures from NHANES-III
12
.  That 
12 
 
study found an estimated prevalence of COPD of 23.4 million (13.9%) among people 
aged 25–75 years.  The estimated prevalence of mild COPD (defined FEV1/FVC <70% 
and FEV1 ≥80% predicted) was 6.9% and moderate COPD (defined as FEV1/FVC <70% 
and FEV1 50-80% predicted) was 6.6%
12
. 
The state-based Behavioral Risk factor Surveillance System (BRFSS)
53
 was also 
used to estimate the prevalence of COPD nationally and statewide
54
.  BRFSS used only 
one question to assess COPD prevalence i.e. “Have you ever been diagnosed with COPD, 
emphysema or chronic bronchitis?”  The 2011 BRFSS was the first year that provided a 
complete estimate of the prevalence of COPD by each state
54
.  According to BRFSS, 6.3 
% of US adults (approximately 15 million) have COPD with the highest prevalence 
among subjects aged between 65-75 years (12.1%)
47,54
.  Prevalence varies by state with 
Kentucky and Alabama having the highest prevalence of COPD (>9%)
54
.  There has not 
been a significant change in prevalence of COPD from 1998 to 2009 and it remains 
mostly stable around 5% among all adults aged greater than 18 years for all gender
55
.  
Age specific prevalence’s and unadjusted prevalence rates of COPD in US adults aged 
≥25 years is shown in figure 1.  Numbers used in creating Figure 1 are taken from Ford 
et. al. article of COPD surveillance in United States from 1999-2011 using BRFSS 
survey
47
.  From the figure, COPD rates gradually increase from age 25 to 75 years but 
decline thereafter due to more mortality among subjects more than 75 years of age. 
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Figure 1 Age specific prevalence of COPD among US adults aged ≥25years (BRFSS) 
 
 
A thorough review of COPD prevalence and trends in mortality in different 
countries were discussed by Rycroft el. al
56
.  According to that review, there is a 
significant variation in the prevalence of COPD worldwide; mainly due to type of 
definitions and classification used to diagnose COPD along with type of survey used to 
estimate the prevalence.  The prevalence is high among men aged ≥75 years with 
decrease in mortality among men in several countries like Australia, while increasing or 
stabilizing among women in countries like USA.  
 
COPD is projected to be the third leading cause of death for both males and 
females by 2030
57
.  In USA According to preliminary reports of deaths from vital 
statistics by Hoyert et. al.
58
, COPD is the third leading cause of death with approximately 


































































The prevalence of COPD is increasing and will continue to climb as our 
population grows.  In the report on COPD surveillance published by Mannino et. al., in 
the year 2000 alone COPD accounted for 8 million physician office and hospital 




Overall there has been a decline in COPD mortality in many countries, but in a 
few countries including the US, Australia and France, the mortality rate has increased in 
women and decreased in men
56
.  In the US, there has been a huge increase in the COPD 
death rate in females that has occurred over the last 20 years: i.e. a rise from 20.1 per 
100,000 in 1980 to 56.7 per 100,000 in 2000 for females versus 73.0 per 100,000 in 1980 
to 82.6 per 100,000 in 2000
12
. 
In summary, COPD is a disease of major public health concern and measures 
must be taken to decrease the rate and improve the quality of life of subjects living with 
COPD.  This project reviews the effectiveness of implementing a COPD disease 
management program (DMP). 
 
Risk factors for COPD 
The most important risk factor for COPD is smoking as documented by numerous 
epidemiological studies, summarized in Table 2.  Although smoking is the most 
important risk factor for COPD
59-62
, not all smokers will develop COPD which implies 
involvement of other factors including genetic predisposition
63
 , socioeconomic status
64
, 
exposure to occupational dust and chemicals
65
, and outdoor air pollution
66
.  An 
interaction between genetic and environmental risk factors increases the risk for COPD.  
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The most common genetic factor associated with COPD is the deficiency of α1 
antitrypsin
67,68
.  Subjects with α1-antitrypsin deficiency have reduced levels of circulating 




Table 2 Epidemiological studies of Smoking and COPD 
 
Several genome wide association studies (GWAS)
69-72
 and candidate gene 
studies
71,73
 had been completed in last few years to begin to identify genes associated 
with COPD and also to understand the pharmacogenetics
74
 of COPD.  Pillai et. al. 
conducted a GWAS in a homogenous case-control cohort from Bergen, Norway (823 
COPD cases and 810 smoking controls) and evaluated the top 100 single nucleotide 
polymorphisms (SNPs) in the family-based International COPD Genetics Network 
(ICGN) study.  Further evaluation of polymorphisms was done among subjects from US 
National Emphysema Treatment Trial (NETT) cohort, Normative Aging Study (NAS) 
Study Type of Study Location Smoking status Risk measure Estimate 
Lokke et. al., 
200660 





Never  Incidence 
rate 
39/401 (9.7%) 
Ever  196/806 
(24.3%) 
Mastrangelo 
et. al., 200361 
Case control study Padova, Italy Never 
(15 cases,  
99 controls) 
Odds Ratio 1 
Former 













survey of England, 
HSE) 
England Never Odds Ratio 1 
Ex-smokers 1.50  
(1.30 to 1.72) 
Current 3.94  






Health study, CHS) 







cohort and Boston Early-Onset COPD population cohort
69
.  From that study researchers 
found two polymorphisms in the α-nicotinic acetylcholine receptor 3/5 locus on 
chromosome 15 that showed definite evidence of association with COPD. 
 
Economic burden of COPD 
  
COPD also imposes a major economic burden in the USA and globally
75,76
.  
According to the American Lung Association, in the year 2010, COPD cost 
approximately $50 billion which included $30 billion in direct health care costs and $20 
billion in indirect costs
77
.  The direct medical cost for COPD has almost doubled since 
1996 when they were $14.5 billion
78
.  Direct costs refer to expenditures related to 
diagnosis, treatment and prevention of disease directly related to COPD, including office 
visits for COPD, investigations related to COPD, medical management costs and 
hospitalization costs related to COPD exacerbation
79
.  Indirect costs are related to 
morbidity and mortality caused by COPD
79
.  Indirect costs are associated with output 
losses (loss of work time and productivity) and family costs as a result of COPD 
consequences
79,80
.  Many studies have estimated direct and indirect costs of CODP in the 
USA and globally
75,80-82
.  Ward et. al. conducted a retrospective study using a public-
payer perspective to estimate direct medical costs of COPD in the USA and these authors 
found that approximately out of $6.6 billion, $2.3 billion was due to the cost of long-term 
oxygen therapy, $1.9 billion was associated with in-hospitalizations usage while the 





A more recent retrospective study using a managed care claims database to 
estimate the direct cost of COPD was done by Dalal et. al
82
 in 2010.  The study includes 
37,089 COPD patients divided into five cohorts i.e. outpatient, urgent outpatient, 
emergency department, standard inpatient admission, and intensive care unit (ICU).   
Mean standard annual COPD-related health care costs (2008 US$) increased across the 
cohorts (P value 0.001), ranging from $2003 for the outpatient cohort to $43,461 for the 
ICU cohort.  Average cost, combining patients from all cohorts, was $3943 which 
included $2731 in medical costs and $1211 in pharmacy cost
82
.  Akazawa et. al. also 
conducted a similar type of retrospective administrative claims data analysis
83
 and 
concluded that COPD patients in the U.S. had significantly more healthcare utilization 
and higher costs in the year prior to COPD diagnosis than matched control subjects.  Teo 
et. al.
75
 conducted a study to estimate direct medical costs of COPD in two public health 
clusters in Singapore from 2005 to 2009 and study found that average cost of COPD was 
$9.9 million per year with hospitalization contributing to approximately 73% of total 
cost. 
According to study by Simoni et. al., among Medicare beneficiaries residing in 
long term facilities, twelve-month COPD-related and all-cause direct expenditures per 
beneficiary were US $7391 and $48,183
84
.  The Center for Medicare and Medicaid 
services reported that approximately 12 percent of Medicare beneficiaries aged 65 years 
and above have COPD
85
.  Blanchette et. al. reported that the respiratory-related costs 
accounted for 22 percent of total all-cause health care costs for among Medicare 
beneficiaries with COPD
86
.  In summary COPD is major contribution to the overall 
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economic burden of healthcare costs in USA and globally with in-patient hospitalization 
contributing a major portion of all COPD related costs. 
 
Chronic Disease Management 
 
Definition of chronic disease management 
Many definitions of chronic disease management have been proposed since this 
innovative approach was introduced in the USA
87-91
.  Epstein and colleagues
88
 defined 
disease management as “ the use of an explicit systematic population-based approach to 
identify person at risk, intervene with specific programs of care and measure clinical 
outcome”.  More recently Faxon et. al.
91
 in 2004 defined disease management as “ a 
multidisciplinary effort to improve the quality and cost-effectiveness of care for selected 
patients suffering from chronic conditions”.  With several definitions in practice, the 
primary goal of disease management is to improve both objective and subjective quality 
of life of subjects with chronic disease. 
In summary disease management is a multidisciplinary coordinated preventive 
intervention focusing on target groups with chronic diseases like diabetes, heart disease, 
and chronic obstructive pulmonary disease with an overall goal to improve both objective 





Disease management Program (DMP) 
 As discussed above, the primary goal of any disease management program is to 
improve overall quality of life for subjects living with chronic conditions and to reduce 
total health care costs.  Several studies have evaluated the effect of disease management 
programs on clinical outcomes among subjects with heart failure, diabetes, and chronic 
obstructive pulmonary disease.  McAlister et. al. conducted a systemic review of 11 
randomized clinical trials of DMP in heart failure and found significant reductions in 
follow up hospitalizations (RR 0.87, with 95% CI: 0.79 to 0.96) for DMP enrollees with  
even greater reductions in recurrent hospitalization if the DMP trial includes follow up by 
a multidisciplinary specialized team rather than limited follow up by telephone.  These 
findings were supported by a recent retrospective study conducted in Spain, which found 
that heart failure subjects who had exposure to a DMP had a lower risk of death and 
readmission due to heart failure
92
.  Apart from heart failure subjects, DMPs are also 
effective in diabetes patients.  Sidorov et. al. evaluated a Health management 
organization (HMO) sponsored DMP for Diabetes and this study found a significant 
improvement in quality of life and reduction in cost for those enrolled in the program
93
. 
Our present study will focus on the effectiveness of the COPD management 
program by comparing several clinical outcomes and claims related costs for those 





COPD management program 
  
As discussed previously, COPD is a serious public health problem with major 
extrapulmonary manifestations of disease leading to chronic morbidity and resulting in 
the fourth leading cause of mortality in USA.  COPD also imposes a major economic 
burden not only in the USA but globally with total expenditures estimated to be upwards 
of $50 billion, including both direct and indirect cost
77
.  Since COPD is a chronic disease 
with multiple co-morbidities, a multidisciplinary approach to disease management is 
recommended to in order to improve quality of life and reduce health care utilization 
related to COPD exacerbations
94-96
.  Several studies have been published in the last 10 
years regarding the role of disease management program in COPD but the results are 
inconsistent and inconclusive.  Most of the studies evaluated clinical outcomes and self-
reported quality measures (like St George Respiratory Questionnaire, COPD assessment 
test) with few studies evaluating cost effectiveness of the program. 
Components of COPD disease management programs include self-management, 
patient centered education, case management, home-based pulmonary rehabilitation and 
an action plan for identification and treatment of exacerbation
97-99
.  Some studies 
evaluated the effect of one component, like self-education, or combined more than one 
component in an integrated approach to study different clinical outcomes with the goal of 
improving quality of life on COPD subjects
97
.  Another approach, called the Proactive 
Integrated care (PIC) approach, is a combination of disease specific education and self-
management principles along with simple remote monitoring platform and was used by 
Koff et. at.
99
 and Linderman et. al.
98
.  Fan et. al. used a Comprehensive Care 
Management Program (CCMP) including four individual COPD education sessions, one 
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group session, an action plan for exacerbations, and scheduled proactive telephone calls 
for case management
100
.  A detailed review of self-management education was done by 
Effing et. al.
101
.  The review includes results from 14 different trials and reported a 
significant reduction in hospital admission among self-management group versus usual 
care and also significant reduction in SGRQ score and BORG dyspnea score for those 
who enrolled into self-management program. 
 A recent multi-center randomized clinical trial was completed by Fan et. al.
100
 that 
included COPD patients from 20 Veteran Affairs hospital with the objective to determine 
the efficacy of CCMP in reducing COPD hospitalization. The trial was stopped 
prematurely due to excess mortality in the intervention group (28 deaths) versus the 
comparison group (10 death) with hazard ratio of 3 (95% CI: 1.46 to 6.17; P = 0.003).  At 
the time of termination, the 1-year cumulative incidence of COPD-related hospitalization 
was 27% in intervention group versus 24% in the usual care group (hazard ratio, 1.13 
[95% CI, 0.70 to 1.80]; P = 0.62)
100
.  A similar study by Mehring et. al. evaluated 
retrospectively the effect of a German Disease management program on COPD
96
.  This 
study found significant reductions in prescription of theophylline and oral corticosteroids 
along with an increased utilization of patient education, smoking cessation and a 
reduction in the occurrence of exacerbations
96
 and study conclude that the German DMP 
for COPD was effective in enhancing the quality of care but was not able to prevent 
increase in emergency admissions for stable COPD cohort. 
Moullec et. al. used a combination of patient centered education and case 
management as an integrated care approach to evaluate its effectiveness and found 
significant reductions in COPD related hospitalization (OR: 0.44; 95% CI: 0.23-0.85) 
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compared to usual care
97
.  In the proactive integrated care approach by Linderman et. al., 
there was a significant improvement in SGRQ score (from 50.8 to 39.2), BODE index 
(4.3 to 2.9), mMRC (from 2.0 to 1.7) and six minute walk distance (from 265.1 to 319.4) 
after the implementation of proactive integrated care approach among COPD patients. 
 
Respiratory measures in COPD 
  
As discussed above spirometry is the most important pulmonary function test not 
only to diagnose COPD but also to assess the prognosis of COPD patient.  Apart from 
spirometry, other measures routinely performed among COPD patients includes six 
minute walk test (6 MWT), COPD assessment test (CAT), St George respiratory 
questionnaire (SGRQ) and BODE index. 
 
Six Minute Walk Test (6 MWT) 
The 6MWT is an important measure of daily living among COPD subjects
102
, and 
simply measures the distance that a patient can quickly walk on a flat, hard surface in a 
period of 6 minutes.  Functional and exercise capacity is determined by the integrated 
response of multiple systems, including the pulmonary, cardiovascular, hematopoietic, 
skeletal and metabolic
102
.  The 6MWT does not provide specific information on the 
function of each organ and system involved in the exercise mechanism; instead, it serves 
as a surrogate estimate of the collective mechanism
102
. 
In clinical practice, the 6MWT is used for measuring the response to medical 
interventions for patients with moderate to severe heart or lung disease
102
.  Solway et al. 
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(2001) performed a qualitative review of measurement properties of the shuttle walk test 
and 6MWT and concluded that exercise performed was similar to a symptom-limited, 
maximal, incremental treadmill test
103
.  The shuttle walk test is more difficult to 
administer, requires more equipment, and is less reflective of activities of daily living
103
.  
The 6MWT is easy to administer, better tolerated, and more reflective of activities of 
daily living.  Therefore, currently, the 6MWT is the test of choice when administering a 
functional walk test for clinical or research purposes especially among COPD cohort
102
. 
Hernandes et. al. investigated the reproducibility of the 6 MWT in COPD patients 
in a retrospective cohort study and also quantified the learning effect between two 
6MWTs performed on subsequent days
104
.  The study
104
 found that, on average, the 
second 6MWT increased by 27 m (or 7%), and 82% of patients showed improvement in 
their second 6MWT distance.  Additional factors associated with improvement on the 
second six minute walk distance (6MWD) by >42 m are first 6MWD >350 m, Charlson 
index <2 and body mass index < 30 kg/m
2
. 
 By conducting the 6MWT in the follow up visits of COPD subjects, it is 
important to understand whether change in walking distance observed over time 
represents a clinically important effect on subjects overall quality of life because a 
change in 6MWD from previous values may be significant statistically but not 
clinically
105,106
.  Holland et. al. conducted a prospective study to establish the minimal 
important difference (MID) in 6MWD in COPD subjects and authors found that a MID of 
25 meter (95% CI: 20-61 meter) in COPD or a 14% change in 6MWD compared with 
baseline represents clinically important effect; but the % change is less sensitive (0.70) 





MMRC Dyspnea Scale 
 The modified Medical Research Council (mMRC) scale is a validated tool and 
most commonly used scale to assess dyspnea in subjects with chronic respiratory lung 
disease
107
.  See Appendix 4 for MMRC dyspnea scale.  To assess health related quality of 
life using MMRC, a cross-sectional study of 328 COPD patients was conducted and 
mMRC was found to be a good and reliable indicator
108
.  Currently, GOLD supports the 






BODE index is a multidimensional staging tool first developed and validated by 
Celli. et. al. in 2004 to assess the pulmonary and systemic manifestation among subjects 
with COPD
110
.  The BODE index consists of four components: BMI [B], Obstruction [O] 
as measured by FEV1, Dyspnea [D] severity as measured by Modified Medical Research 
Council (MMRC) Dyspnea scale, and exercise [E] capacity as measured by distance 
covered in 6 MWT
110
.  Before the development of the BODE index, the only variable that 
could predict mortality among COPD patients was FEV1
111
.  As COPD is a systemic 
disease and FEV1 will explain only the respiratory component of COPD, it is important to 
include  measures that also reflect systemic components and exercise capacity  along with 
spirometric measures which predicts all-cause mortality, CODP specific mortality and 






Development and validation of BODE Index
110
   
Celli. et. al. used several variables to predict mortality among 207 COPD patients.  
These variables includes age, gender, smoking, FEV1, FVC, 6 MWT, BMI, degree of 
dyspnea measures suing MMRC dyspnea scale, functional residual capacity, inspiratory 
capacity, hematocrit, and albumin level
110
.  By evaluating the association of each of these 
explanatory variables to predict one year mortality using stepwise logistic regression 
method, researchers found only four variables (BMI, FEV1, dyspnea severity and 6 
MWD) that had a strongest association to predict mortality.  The BODE index was then 
created using those 4 variables.  The BODE index can be calculated by summing a score 
assigned to each component as outlined in the table below.  For all-cause mortality, the 
HR was 1.34 (1.26 to 1.42; p < 0.001) and for respiratory death it was1.62 (1.48 to 1.77) 
for every one point increase in BODE index.  The C statistic of BODE index to evaluate 
the ability of the index to predict death was 0.74 versus 0.65 for FEV1 alone (0.74 v 
0.65).  The BODE index will range from 0-10, with higher scores indicating a high risk 
of mortality (See Appendix 5 for complete scoring of BODE index). 
 Since the development of BODE index in 2004, many studies had been done 
among COPD subjects to predict mortality
113
, to predict hospitalization
114
, and to 
compare BODE with GOLD criteria to assess anxiety and depressive symptoms
115
.  
Study by Cote et. al. used BODE index to compare the outcome among COPD patients 
who received pulmonary rehabilitation (PR) versus those without PR and the study found 
that at the end of 1 year the BODE index improved by 19% among patients in PR group 
and worsened by 4% among patients in no PR group
116
.  Ong et. al.
114
 conducted a study 
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to predict hospitalization for COPD and found that the BODE index is a significant better 
predictor for hospitalization than FEV1. 
St George Respiratory questionnaire 
St George Respiratory questionnaire (SGRQ) is the metric to measure the health 
related quality of life of subjects with respiratory problems like COPD and Asthma
117,118
.  
SGRQ was first developed and validated by Paul Jones from St George University 
London
119
.  See Appendix 6 for the detailed SGRQ questionnaire.  The original SGRQ 
consisted of 76 items categorized into three sections
119
  
1. Symptoms related items: consists of item related to cough, wheeze, 
breathlessness and its severity 
2. Activity related items: consists of questions related to activity that is affected 
by breathlessness 
3. Impact related items: consists of items related to the impact (either social or 
psychological) due to breathlessness 
 
Interpretation of scores: 
A score can be calculated individually for each section (i.e. symptom score, 
activity score, and impact score) as well as a total score
119,120
.  Factors taken into 
consideration for calculating score include age, gender, weight, disease duration, current 
and worst pulmonary function test measures
119
.  The SGRQ score ranges from 0 to 100; 
with higher scores indicating more severe disease and causing more limitations in daily 
living of COPD subjects
119,120
.  A study by Ferrer et. al. relating to the interpretation of 
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the quality of life scores from SGRQ, found that the strongest association of SGRQ total 
scores is % predicted FEV1 along with smoking, age, gender and education which 
independently associated with the SGRQ total score
121
.  The current American version of 
the SGRQ consists of 50 items classified into the same three categories
122
. 
As full version of SGRQ is lengthy and more generalized.  Meguro et. al. 
developed a shorter and improved version of SGRQ designed specifically for COPD 
patients called the SGRQ-C
123
.  This study was conducted with the aim of identifying 
items that are weak, have low response rate, redundant and fit poorly with other items 
using the Rausch reduction technique.  A total of 10 weaker items were identified and 
removed without altering the performance of the instrument
123
.  One item that was 
removed due to low response rate was employment because most of subjects were retired.  
The SGRQ-C has been developed using COPD data only, so it is valid for subjects with 
COPD
123
.  In conclusion SGRQ-C is short, reliable, valid, and contains most of the items 
from original SGRQ and the principal differences from the original SGRQ are smaller 
number of items (reduction from 50 to 40 items). 
Several studies had been published to identify and interpret the threshold for 
clinical significant change in SGRQ in COPD patients
124-126
.  Based on a study by Jones 
et. al. 2002, an improvement of mean score of 4.3 is considered an effective treatment 







COPD Assessment Test (CAT) 
COPD assessment test is a short, simple questionnaire to measure the quality of 
life and monitor the health status of person’s living with COPD.
127,128
  It’s a simple 
questionnaire that is useful to patients and also to clinicians to assess the severity of 
COPD.  Because of the length of several other questionnaires [like SGRQ, COPD clinical 
questionnaire, chronic respiratory questionnaire (CRQ)] to measure health related quality 
of life in COPD subjects; there is a need to create a short and easy questionnaire for 
COPD subjects.  This led to the development of COPD assessment test (CAT) by Dr. PW 
Jones in 2009
127
.  See Appendix 7 for detailed CAT questionnaire. 
 Development of CAT and Interpretation of CAT score
127
:  Initially the CAT 
consisted of 21 questions but following a structured approach to item reduction, the final 
CAT consists of 8 questions assessing cough, phlegm, chest tightness, breathlessness, 
activities, confidence, sleep and energy.  An item reduction process was used to create a 
tool which is bias free from demographic factors such as sex, country, language spoken 
and the instrument which has a good reliable measurement property.  Countries studied 
for the development of CAT includes USA (n=229), Spain (n=369), The Netherlands 
(n=109), Germany (n=431), France (n=294), Belgium (n= 71).  By studying in 6 different 
countries for testing internal consistency, the CAT score provides a reliable measure of 
COPD severity independent of the language spoken.  The CAT scores range from 0-40 
with the higher scores indicating more severe impact of COPD on daily life.  A reduction 






 Since the development of the CAT score, many studies had been published to 
discuss the properties of CAT score
130
, responsiveness of CAT following acute 
exacerbation and pulmonary rehabilitation in COPD subjects
128
.   The CAT score is a 
good reliable tool to measure the severity of COPD GOLD stage (Stage I: 16.2 ± 8.8, 
Stage II: 16.3 ± 7.9, Stage III: 19.3 ± 8.2, Stage IV: 22.3 ± 8.7) and has a strong 
correlation with SGRQ (r = 0.8, p value < 0.0001) suggesting that the patient’s response 




Fractional Exhaled Nitric Oxide 
 
FENO testing is a simple noninvasive test that will measure the amount of nitric 
oxide in exhaled air
131
.  It is a marker for eosinophilic inflammation in respiratory 
diseases like COPD and asthma
132
.  ATS published guidelines on the measurement of 
FENO and how to interpret the level of FENO in COPD and Asthma
131
.  FENO is 
measured in parts per billion (ppb) and based on its value can categorized into three 
levels low (<25 ppb), medium (25-50 ppb) and high (>50ppb).  The primary role of 
FENO in COPD patients is to measure the level of inflammation that will predict the 
response to inhaled steroids.  Several studies strongly support the association of 
eosinophilic inflammation, as measured by high FENO, with the response to inhaled 
steroid treatment
133-135
.  In a case control study by Ziekowski, a higher baseline FENO 
level in COPD subjects was directly related to significant improvements in FEV1 after 
treatment of inhaled steroids.  
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General health measures 
 
Duke Profile 
The Duke profile is a self-report instrument widely used to measure and assess 
overall health as an outcome in medical interventions and health promotion programs like 
chronic disease management programs
136
.  The Duke health profile is the shorter version 
of the original 67 item Duke UNC health profile
136
.  The current version consists of 17 
items with respective questions responses to a 3 point Likert scale and can be completed 
in 5-8 minutes
136
.  See the Appendix 8 for Duke Health profile questionnaire.  From the 
17 items, 6 summary scores are calculated for health function and include physical 
health, mental health, social health, general health, perceived health, self-esteem; while 4 
summary scores for health dysfunction includes anxiety, depression, pain and 
disability
136
.  Duke health profile is available in many languages and several studies had 







 PHQ-9 is an instrument to screen and diagnose depression139,140.  It is also used 
clinically to monitor and measure the severity of depression in different clinical 
conditions like prenatal depression
141
, depression in HIV patients
142
 and also in COPD 
patients
143
.  It consists of 9 questions with a total score ranging from 0 to 27 as each item 
is scored from 0 (not at all) to 3 (nearly every day).  (See Appendix 9 for detailed PHQ9 
questionnaire).  Scores from 5-9 is mild depression, 10-14 is moderate depression, 15-19 
is moderately severe depression and >20 is severe depression
140
.  Diagnostic validity of 
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, and in USA
140
.  Minimal clinical important difference for PHQ9 measured on a 





 As COPD is strongly associated with sleep disorders like obstructive sleep 
apnea
147,148
 it is important to assess sleep hygiene among COPD patients.  Most 
commonly used measure for sleep disorders are Epworth sleepiness scale
149
 and Berlin 
questionnaire
150
. Epworth sleepiness scale was first invented by Johns et. al. in year 1991 
as a new method of measuring daytime sleepiness
149
.  It’s a valid, reliable measure to 
quantify daytime sleepiness in different countries and it’s a valuable tool for clinical 
practice and multicenter research
151,152
.  The Berlin questionnaire consists of three 
categories of questionnaire related to risk of having sleep apnea and depending on their 
response to questionnaire subject can classified as high risk (if 2 or more categories 
where the score is positive) or low risk  (if 1 or no categories where the score is 
positive)
150
.  See Appendix 10 for a detailed Berlin Questionnaire and scoring and 
Appendix 11 for Epworth sleepiness scale. 
 Table 3 summarizes the range score and minimal clinical important difference for 
all the important parameters (both general and respiratory) measured in COPD subjects to 





Table 3 Summary of Respiratory and General Measures in COPD 












MMRC Dyspnea 0-5 Lower value 
indicates less severe 
dyspnea 
 




more impact of 





BODE index 0-10 Higher score 





0-40 Higher scores 
denote a more 
severe impact of 














Duke profile 0-100 For health measures 
high score means 






Disease management, a multidisciplinary approach proposed to enhance the 
quality and cost-effectiveness of health care for chronic conditions
91 
has been defined as 
“an approach to patient care that emphasizes coordinated, comprehensive care along the 
continuum of disease and across health care delivery systems”.  The purpose of the 
present study is to evaluate the effectiveness of the COPD disease management program 
implemented at the University of Louisville in year 2011.  We conducted a retrospective 
comparative effectiveness research study of pulmonary clinic patients with Chronic 
Obstructive Pulmonary Disease (COPD) that compares clinical outcomes of those 
enrolled in the disease management program to those under usual care.  Primary 
outcomes included pulmonary function test (PFT) results, six minute walk distance, 
quality of life measures and cost related to COPD.  The disease management program 
was intended to improve the quality of life of persons living with COPD by reducing the 
number of exacerbations and in-patient hospitalizations, improving overall respiratory 
health and reducing the burden of disease and mortality. 
 
The disease management program, per se, is an innovative approach to improve 
the quality of life and overall health of persons living with COPD.  This study will be the 




propensity score (PS) method to evaluate the effectiveness of a COPD disease 
management program by comparing important clinical outcomes between DMP group 
and usual care group.  Propensity score matching is a common method used in 
comparative effectiveness research and in pharmacoepidemiology
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.  The PS estimates 
each patient’s probability of enrollment in the intervention group rather than usual care.  
Propensity score is a probability ranging from 0 to 1.  Subjects with a low propensity 
score will have a lower probability of enrolling in the disease management program.  
Similarly, a higher score suggests a higher probability of enrolling in the disease 
management program.  The propensity score can be used as a matching variable or as a 
covariate in regression analyses; we opted for the latter approach. 
 
Goals 
 The overall goal of the disease management program is to delay the progression 
of COPD, enhance quality of life, improve clinical outcomes, and also to reduce health 
care utilizations and overall health care costs. 
 
Specific Aims 
 Specifically, the following aims were proposed to assess and evaluate the 
effectiveness of the disease management program.  Aim 1 will evaluate the clinical 





Aim 1  
a) To test for differences in key clinical parameters, such as the pulmonary function test 
and six minute walk distance, between COPD subjects enrolled in disease management 
program and those who are in usual care. 
b) To compare longitudinal changes in respiratory and general measures among subjects 
in disease management program. 
 
Aim 2 




Primary Hypothesis 1 
Research Hypothesis (H1a):  Subjects participating in the disease management program 
will experience better clinical outcomes compared to patients receiving usual care. 
Null Hypothesis (H0a):  Implementation of disease management program will not 
improve clinical outcomes among COPD subjects comparing to COPD subjects under 
usual care. 
 
Research Hypothesis (H1b):  Subjects participating in the disease management program 
will improve their clinical outcomes longitudinally from baseline. 
Null Hypothesis (H0b):  Implementation of disease management program will not 
improve clinical outcomes among COPD subjects longitudinally from baseline. 
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Primary Hypothesis 2 
Research Hypothesis (H2):  Health care costs for subjects enrolled in the disease 
management program will be lower than for subjects receiving usual care. 
Null Hypothesis (H0):  Implementation of disease management program will not lower 
cost for COPD subjects than for subjects receiving usual care. 
 
Methods 
 We conducted a retrospective observational cohort study of COPD subjects using 
clinical data from medical records and cost data from a claims dataset. 
The COPD subjects were obtained from three data sources: 
i. From Administrative claims dataset: Male and female University of Louisville 
health plan members who are beneficiaries of United health care during the time 
frame from January 1
st
 2009 through December 31st 2013 (five years). 
ii. From Pulmonary Function Test dataset: Male and female subjects who had 
physician diagnosed COPD and had pulmonary function testing done at the 
University of Louisville hospital and/or clinics. 
iii. From Disease management dataset: Male and female subjects diagnosed with 
COPD and are under University of Louisville Disease Management Program 
(DMP).  See Appendix 3 for a detailed description of University of Louisville 
DMP for COPD. 
 Inclusion criteria for the study included physician diagnosed COPD while 
exclusion criteria include pregnant women and non-ambulatory subjects.  The study 
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subjects were divided into two groups based on their enrollment into the disease 
management program.  Group A included COPD subjects in the disease management 
program (DMP group).  Group B included COPD subjects in the usual care (Usual Care 
group), including those subjects who have health care claims for COPD (from claims 
data) or whose physicians diagnosed COPD and are cared for at the University of 
Louisville clinics. 
Sources of Data 
 Data was collected primarily from two sources: 
i. Clinical charts 
 Data from the clinic charts were retrieved electronically through Allscripts
™
 
electronic medical record system.  These data included demographics, co-morbidities, 
pulmonary function test parameters, six minute walk distance, general measures and 
sleepiness scales. 
ii. Claims data 
 Navigator MD Design 180 was used to retrieve claims data.  Navigator MD is a 
data analytic company which focuses on processing administrative claims data through 
its product named Design 180.  Design 180 is flexible and easy to use database software 
that can query claims data for specific medical conditions like COPD
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.  Subjects who 
had claims for COPD were retrieved from the data set first.  Costs related to COPD and 
other major co-morbidities like asthma, heart disease, hypertension, diabetes mellitus, 
arthritis, rhinitis, depression were extracted from the dataset in the Microsoft Excel 
format.  Costs for those who enrolled in the disease management program were collected 
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as COPD related costs in the first, second and third years of the program.  Costs of COPD 
subjects in usual care were collected from January 1
st
 2009 to December 31
st
 2013.  
Person-years for each subject were calculated from the effective and termination date of 
the health coverage plan.  Costs were calculated as average cost per person per year.  
Costs related to COPD were further classified into in-patient hospitalization cost, out-
patient hospitalization cost, office cost, laboratory cost and home cost.  Home service 
costs included those associated with oxygen concentrator, nebulizer, and continuous 
positive airway pressure device. 
 
Statistical methods  
Predictors (independent or explanatory variables) 
 The key variable in analysis was group membership: Group A (Disease 
management group) or Group B (Usual care group).  Other covariates were age, gender, 
race, time of measurement of respiratory and general measures, co morbidities (diabetes, 
heart disease, hyperlipidemia, hypertension, depression, asthma, rhinitis, osteoporosis, 
obstructive sleep apnea).  Time variable was categorized as 0 (baseline), 6 months, 12 
months, and 18 months with the increment of 6 months from baseline.  For DMP group, 0 
months means at the time of enrollment into disease management program and for usual 
care group first pulmonary function test measure available from PFT dataset was consider 
as 0 month and follow-up longitudinal values were rounded up to nearest 6 months, 12 
months, etc.  The propensity score was used as a covariate in regression analysis. 
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 For each subject, the baseline probability of participation in the disease 
management program was calculated by the propensity score method using logistic 
regression analysis.  Variables included in logistic regression analysis included baseline 
age, gender, race, co-morbidities like asthma, rhinitis, diabetes, heart disease, 
hyperlipidemia, sleep disorders, arthritis, hypertension and osteoporosis. 
 At baseline, chi-square test for categorical variable and t-test for continuous 
variable was used to check for any difference between the two groups.  For comparison 
between two groups (DMP group versus Usual care group), Odds Ratio (OR) was used as 
a risk measure along with 95% CI and associated P value.  P value < 0.05 was considered 
statistically significant. 
Outcome (dependent variables) 
 Absolute and predicted FEV1, FVC, quality of life measures (Duke, PHQ9 
questionnaire), respiratory measures (6MWD, CAT score, BODE index, mMRC scale), 
cost related to COPD (from claims data). 
 To compare longitudinal changes in quality of life measures like SGRQ, CAT 
score, mMRC scale, BODE index, six minute walk distance and PFT measures in DMP 
group paired t-test were performed to check for any significant difference in respiratory 
and general measures from baseline.  Longitudinal values of absolute FEV1 (ml) and 
absolute FVC (ml) were displayed by using CDC Spirola software.  Multiple linear 
regression analysis was performed to assess the rate of deterioration of various clinical 
parameters like FEV1 and FVC between two groups.  Regression models were also 
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adjusted for propensity score.  Regression coefficient and P value intervals will be 
reported for comparing clinical outcomes between two groups.   
 
 
Regression model for clinical outcomes:  
Yij = α + β0X1i + b0i + (b1i + β1) X2ij + β2 X1iX2ij + €ij; 
),0(~ 200 ibi Nb  ; ),0(~
2
11 ibi Nb  ; ),0(~€ij
2N   
Where “Y” is the dependent or response variable (for e.g. absolute or predicted 
FEV1, absolute or predicted FVC); “X1” is an independent indicator variable for 
DMP group (1) or usual care group (0);‘i’ is the subject; ‘j’ is time; X2 is the time 
in months (0, 6, 12, 24); α + β0  and β1+ β2 are intercepts and slopes for DMP 
group respectively; b0i is the random deviation of the i
th 
subject from the overall or 
population’ intercept (β0); b1i is the random deviation of the i
th
 subject from the 
population slope (β1), β1 is the estimate slope for variable X1; Yij is the outcome 
variable value (for e.g. FEV1) of subject ‘i’ at time ‘j’.  
 
 
 Cost analysis was done by comparing the cost related to COPD among subjects in 
DMP group versus those under usual care.  These costs included total COPD cost, and 
also sub-categories of cost like office visit cost, in-patient hospitalization (IPH) cost, out-
patient hospitalization (OPH) cost, pharmacy cost, cost related to home care and 
laboratory cost.  Regression analysis will be performed for cost related to COPD. All the 
analysis will be done using SAS 9.3 Statistical software. 
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Linear regression model for cost 
Yi = α + β1X1i+ β2X2i + β3X3i + €i;  
where Yi is the total cost related to COPD from 2009-2013; X1 = 1 if less than one year 
in program, else 0; X2 = 1 if one to two years in program, else 0; X3 = 1 if more than 
three year in program, else 0; β1, β2, β3 are regression coefficients respectively for X1, X2 
and X3 
 
Sample size calculation 
Sample size was calculated based on difference in 6MWT between two disease 
management group and usual care group.  If the mean difference in 6MWT distance 
between the two group is 7.5 with standard deviation of 17.5 in the both groups, the 
sample size needed to detect a difference with alpha level of 0.05, and power of 80% will 
be 48 (for intervention group) and 144 (for usual care group) based on t-test and 
allocation ratio of 3:1 usual care versus DMP group.  In this study, we have a total of 52 




Descriptive statistics and baseline characteristics of the study subjects 
A total of 52 subjects were enrolled into disease management program between 
February 1
st
 2011 and December 31
st
 2013: 37 in 2011, 11 in 2012 and 4 in 2013.  The 
usual care group consists of 662 subjects diagnosed with COPD from the University of 
Louisville Pulmonary function test database or subjects who had claims related to COPD 
from the Navigator MD claims database.  Table 4 describes the baseline demographic 
characteristics of both the groups.  There is a significant difference in average age of 
subjects between the two groups (54.2 in DMP versus 58.3 in usual care; P value 0.0094).  
41% of subjects in usual care group are current smokers and only 28.8 % in DMP group 
but the difference is not statistically significant (P = 0.07).  Both groups have 
approximately same number of white subjects (P value 0.77). 
Table 4 Baseline characteristics of study subjects 
 All subjects DMP Group Usual Care 
Group 
DMP vs.  
UC group 
N 714 52 662 P value 
Baseline Age 58.1 ± 11.1 54.2 ± 7.4  58.3 ± 11.2  0.0094 
Male gender 334 27,   51.9  307, 46.3  0.44 
Race     
     White 367 40,   76.9  327,   75.1  0.77 
     AA 117 11,   21.1  106,   24.3   
Smokers     
     Current 177 15,   28.8  162,   40.7  0.07 
     Former 247 31,   59.6  216,   54.2  0.23 




Additional data at baseline on sleep and FENO were collected from subjects 
enrolled in the disease management program.  Mean ± SD for baseline FENO level is 
23.8 ± 15.3 and Epworth sleepiness scale is 7.5 ± 4.5.  Total of 31 (59.6%) subjects had 
high baseline Berlin score in DMP group.  Based on COPD GOLD stage at the time of 
enrollment, 29 subjects have stage 1 COPD, 16 subjects have stage 2, 6 subjects have 
stage 3 and only 1 subject has Stage 4. 
 
Comorbidities 
 Table 5 describes the prevalence of comorbidities in both groups.  The DMP 
group has a high prevalence of asthma, rhinitis, hyperlipidemia, osteoporosis and 
obstructive sleep apnea.  Table 5 also presents unadjusted relative risks for comparing 
different morbidities between two groups.  The diagnosis of asthma is a labelled 
diagnosis based on their pre bronchodilators pulmonary function test and high prevalence 
among DMP group is likely due to increased screening for asthma at the time of 
enrollment in the disease management program.  There is no significant difference in the 
prevalence of depression and heart disease between two groups.  These comorbidities 









Table 5 Prevalence of Co-morbidities among the study subjects 
 All subjects 
(N=714) 







 n % n % n %   
Asthma 149 22.1 28 53.8 121       17.9 2.77 <0.0001 
Rhinitis 220  34.1 35       67.3  195       31.3  2.14  <0.0001 
Arthritis 238  35.3 26       50.0  212       64.1 1.46  0.02 
Depression 141  20.1 16       30.7  125        20.0  1.53  0.06 
Heart Disease 314  46.5 25       48.0 289 46.3 1.03  0.8 
Hypertension 396,  58.7 37      71.1 359      57.7 1.23  0.058 
Hyperlipidemia 270,  40.1 31      59.6 239       38.4 1.55  0.002 
Diabetes 160  23.7 18       34.6  142      22.8  1.51  0.055 
Osteoporosis 138  20.5 19       36.5 119      19.2 1.90  0.002 
Obstructive Sleep 
Apnea 
116 26.2 26  50.0 90        23.0 2.17  <0.0001 
 
Propensity score calculation 
Table 6 Logistics regression model for propensity score calculation 
 Odds Ratio P value 
Age 0.91     <0.001 
Male Gender 1.99     0.07 
Asthma 4.76     <0.0001 
Rhinitis 3.46     0.0006 
Arthritis 2.58     0.01 
Heart Disease 1.18     0.66 
Hypertension 0.96     0.92 
Hyperlipidemia 2.03     0.06 
Diabetes 0.97     0.94 
Depression 1.09 0.82 
Osteoporosis 0.91     0.82 
 
As discussed above, propensity is the probability of being enrolled in the disease 
management program after controlling for important variables.  Multiple logistic 
regression method was used to calculate the probability of each subject being enrolled in 
the disease management program rather than usual care.  Subjects who suffered from 
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asthma, rhinitis and arthritis were significantly more likely to enroll in the disease 
management program (Table 6). 
 
 
Figure 2 Distribution of Propensity score in DMP group and Usual care group 
  
Distribution of probability for both groups is shown in figure 2.  Average 
propensity score in disease management group were 0.34 versus 0.14 in usual care group.  
From the figure 2 there is an overlap in the distribution of propensity score between 
disease management group and usual care group.  The propensity score has been 
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incorporated as a covariate in multiple regression analysis when comparing primary 
outcomes like FEV1, FVC, and cost related to COPD. 
Clinical effectiveness of the program 
 
 The clinical effectiveness of the program was assessed by both general measures 
and respiratory measures.  General measures like PHQ9 (for assessing depression) and 
Duke Profile (for assessing general health) were used among COPD subjects in the DMP 
group.  Respiratory measures like pulmonary function test, SGRQ, CAT score, BODE 
index, 6MWT and MMRC dyspnea scale were used to assess the severity of disease and 
impact of COPD on individual’s daily activities.  Six minute walk distance and 
pulmonary function test (absolute and % predicted values of FEV1 and FVC) were 
primary outcomes used to compare two groups and also to compare longitudinal changes 
within each group from their baseline values. 
Longitudinal changes of General Measures in DMP group 
 
Table 7 represents the longitudinal changes of PHQ9 and Duke Profile among 
subjects in DMP group. 
 
 
Table 7 Longitudinal changes of general measures in DMP group 
 0 month 12 month 24 month 
PHQ9 (n,  
Mean ± SD) 
19 
6.3 ± 5.4 
30 
4.0 ± 4.4  
13 
3.1 ± 2.1* 
    
DUKE (n,  
Mean ± SD) 
52, 
64.1 ± 17.4 
30 
71.6 ± 16.7* 
19 
70.8 ± 18.7* 







PHQ9 is a measure for depression; lower values indicate fewer depressive 
symptoms.  At baseline, the average PHQ9 was 6.3 which improved at the end of 12 
months (mean = 4) and at 24 months (mean = 3.1).  Figure 3 depicts longitudinal changes 
in PHQ9 (mean ± SE) every six months from baseline to 30 months.  There is a gradual 
decline in PHQ9 from baseline to 30 months except for a surge from 12 to 18 months.  
PHQ9 was implemented later in the program resulting in missing baseline PHQ9 values 
for 33 subjects.  Notwithstanding the small number of subjects, change in PHQ9 from 
baseline is statistically significant at 24 months and we can conclude that disease 
management program significantly improves depressive symptoms among COPD 




Figure 3 Longitudinal changes in PHQ9 in DMP group 





















Duke profile is a self-reported measure of general health status and higher scores 
are better.  At baseline, the average duke score was 64.1 which were improved at the end 
of 12 months and 24 months.  Figure 4 depicts longitudinal changes in duke score (mean 
± SE) every six months from baseline to 30 months.  There is a gradual improvement in 
duke score from baseline to 12 months.  Notwithstanding score declined slightly at 18 
and at 30 months it is still significantly high than baseline.  In conclusion, the disease 
management program improves general quality of life of COPD subjects over baseline. 
 


























Longitudinal changes of Respiratory Measures in DMP group 
 
The respiratory measures followed longitudinally among subjects in DMP group 
include St George Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), 
mMRC dyspnea scale, BODE index along with pulmonary functions test and Six Minute 
Walk Distance (6MWD).  Table 8 summarizes longitudinal changes of SGRQ, CAT 
score and mMRC dyspnea scale among subjects in DMP group at baseline, 12 months 
and 24 months.  
 
Table 8 Longitudinal changes of Respiratory measures in DMP group 
 0 month 12 month 24 month 
SGRQ (n,  
Mean ± SD) 
52,  
37.1 ± 17.1 
29, 
28.4 ± 16.1* 
11, 
30.2 ± 16.1 
    
CAT score (n,  
Mean ± SD) 
14, 
18.4 ± 6.7 
22, 
12.2 ± 5.9 * 
18, 
14.2 ± 7.7 
    
mMRC (n,  
Mean ± SD) 
50, 
0.56 ± 0.7 
32, 
0.46 ± 0.6 
21, 
0.95 ± 0.8 







St George Respiratory Questionnaire (SGRQ) 
 
 
SGRQ is an instrument used among obstructive lung disease subjects to measure 
impact on overall health, daily life, and perceived well-being.  Score is ranging from 0 to 
100, higher the score indicates more severe limitation.  At baseline average SGRQ score 
was 37.1 which were improved at the end of 12 months (P = 0.02) and 24 months from (P 
= 0.21).  Figure 5 depicts longitudinal changes in SGRQ score from baseline.  There is 
slight deterioration in score at 24 months but it is still low from baseline.  The difference 
in SGRQ after 12 months is not only statistically significant but also clinically significant 
as the minimal clinical important difference for SGRQ is 4 for effective treatment thus 
we can conclude that there is a significant improvement in overall health, daily life and 
perceived well-being of COPD subjects after enrollment in the disease management 
program. 
 




























COPD Assessment Test (CAT)  
 
 
CAT is a shorter version of SGRQ questionnaire and is designed to measure the 
impact of COPD on subject’s life and score can be compared to assess the changes over 
time.  Score is ranging from 0-40 with higher scores indicate more severe impact of 
COPD on an individual’s life.  Figure 6 depicts longitudinal changes in CAT score from 
baseline.  There is significant decline in mean CAT score from baseline to 12 months (P 
= 0.01).   From one year to two year score slightly deteriorates to 14.4, but remains below 
baseline.  Based on minimal clinical important difference (MCID) value of 2 for CAT, 
this measure is also clinically significant at 12 and 24 months. 
 























Modified Medical Research Council (mMRC) Dyspnea Scale 
 
 mMRC is a subjective assessment of breathlessness in respiratory diseases like 
COPD and its value are ranging from 0-5.  Table 9 describes longitudinal comparison of 
changes in scale from baseline to 1 year and 2 years.  mMRC scale decreased by 0.06 at 1 
year (P = 0.57) and increased by 0.20 units at 2 year (P = 0.29) but the changes are not 
statistically significant from baseline. 
Figure 7 Longitudinal changes in mMRC scale in DMP Group 
 
 
Table 9 Longitudinal comparison of mMRC Dyspnea Scale 
 
MMRC Dyspnea scale 
 12 months vs.  
0 month 
24 months vs.  
0 month 































Longitudinal changes of Pulmonary Function Test in DMP Group and Usual Care Group 
 Pulmonary function test is most common spirometry measured among COPD 
subjects.  Table 10 describes longitudinal changes in FEV1 (absolute and % predicted) 
and FVC (absolute and % predicted) for DMP group and Usual care group.  Percent 
predicted FEV1 is defined FEV1% of the patient divided by the average FEV1% in the 
population for any person of similar age, sex and body composition (height)
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.  Out of 52 
subjects, 39 subjects had measured values at 1 year and 23 subjects at 2 year in DMP 
group; while 94 out of 426 subjects had measured values at 1 year and 48 at 2 year in 
usual care group. 
 
Table 10 Longitudinal changes in Pulmonary Function test measures in DMP and Usual 
care group 
 0 month 12 month 24 month 
DMP Group 
 N=52 N = 39 N = 23 
FEV1 (liter) 2.16 ± 0.7  2.27 ± 0.7  2.04 ± 0.8 
% Predicted FEV1  0.67 ± 0.2 0.72 ± 0.2 0.69 ± 0.2 
FVC (liter) 3.49 ± 1.1 3.58 ± 0.9  3.30 ± 1.1 
% Predicted FVC  0.83 ± 0.2 0.9 ± 0.2 0.87 ± 0.2 
Usual Care Group 
 N = 426 N = 94 N = 48 
FEV1(liter) 1.44 ± 0.8 1.37 ± 0.6 1.21 ± 0.56 
% Predicted FEV1  0.50 ± 0.2 0.49 ± 0.2 0.45 ± 0.18 
FVC (liter) 2.78 ± 1.1 2.67 ± 1.1 2.47 ± 1.2 
% Predicted FVC  0.74 ± 0.2 0.74 ± 0.2 0.69 ± 0.2 





Forced Expiratory Volume in one second (FEV1) 
 
Table 11 presents longitudinal comparison of changes in absolute FEV1 at the end 
of 1 year, 2 year and 3 years for both the groups.  From the table subjects in DMP group 
has significant improvement in their absolute FEV1 (140 ml) from baseline to 12 months 
(P value 0.0046).  There is also improvement in FEV1 at 24 months by 30 ml and at 36 
months by 60 ml but the difference is not statistically significant due to less number 
subjects at the end of 2 years and 3 years.  FEV1 in usual care group is monotonically 
declining at 12 months (-5ml), 24 months (-130 ml) and at 36 months (-130ml).  So in 
addition to improvement in general measures, subjects in DMP group had significant 
improvement in FEV1 which is also one of the predictor for mortality among COPD 
subjects. 
 
Table 11 Longitudinal comparison of changes in absolute FEV1 (ml) 
Absolute FEV1 (ml) 12 month vs.  
0 month 
24 month vs.  
0 month 
36 month vs.  
0 month 
DMP Group 









P value 0.0046 0.55 0.36 
Usual Care Group 
















Linear regression estimates for FEV1 as a ‘dependent variable’ while DMP group 
versus usual care, time of measurement of FEV1 and propensity score as an ‘independent 
variable’ is shown in Table 12.  Main effect model will include DMP variable, time and 
interaction between them (Model 1).  Model 2 is an adjusted model with addition of 
propensity score in the regression analysis.  From the results of Model 1, FEV1 for usual 
care group is 1455 ml (estimate for intercept) and for DMP group is 2207.1m l (by 
adding estimates for intercept and DMP group).  Slope for usual care group is -3.77 ml 
which means FEV1 is declining by time in usual care group but in DMP group slope is 
1.126 ml means there is an improvement in FEV1with time and its marginally significant 
(P=0.0536).  From model 2 propensity score was found to be significantly associated 
with FEV1.  AIC and BIC for model 2 is less than model 1 and thus model 2 is a more 
fitted model.  Even after adding propensity score, slope is still positive for DMP group 
(1.001 ml) but not statistically significant (P=0.0916). 
Table 12 Estimates from Linear regression Models for examining changes in absolute 
FEV1 (ml) 
 Model 1 Model 2 
Fixed Effects 
 Estimates SE P value Estimates SE P value 
Intercept 1455 35.97 <0.0001 1349.6 42.74 <0.0001 
DMP group 752.1 108.8 <.0001 527 121.8 <.0001 
Time -3.77 1.057 0.0005 -3.28 1.082 0.0028 
Time*DMP 4.896 2.52 0.0536 4.281 2.523 0.0916 
Propensity score    996.4 240.4 <0.0001 
Error variance 
Intercept 516.2 36.06 <0.0001 493 36.07 <0.0001 
Time 0.039 0.024 0.0542 0.043 0.025 0.0444 
Residuals 39.46 4.109 <0.0001 37.93 4.058 <0.0001 
Model Fitness 
AIC 1199.7 1074.3 
BIC 1216.4 1090.6 




Forced Vital Capacity (FVC) 
 
Table 13 represents longitudinal comparisons of changes in absolute FVC (ml) at 
1 year, 2 year and 3 year in both groups.  FVC is monotonically improving in DMP group 
at the end of 1 year, 2 years and 3 years but the changes were not significant from 
baseline.  But in Usual care group FVC improved only at the end of 1 year, but is 
declining thereafter from baseline. Subjects in usual care group had mean decline of 130 
ml (at 24 months) and 210 ml (at 26 months) in FVC from baseline, but FVC among 
subjects in DMP group monotonically improves from baseline.   
Table 13 Longitudinal comparison of changes in absolute FVC (ml) 
Absolute FVC (ml) 12 month vs.  
0 month 
24 month vs.  
0 month 
36 month vs.  
0 month 
DMP Group 









P value 0.06 0.53 0.49 
Usual Care Group 















Linear regression estimates for FVC as a dependent variable for both the models 
is shown in Table 14.  From the table FVC for usual care group is 2795.8 ml (model 1) 
and for DMP group is 3519.7 ml.  Here also slope for FVC is negative (-3.43 ml) for 
subjects in usual care group and positive for subjects in DMP group.  For every one 
month increase in time, subjects in usual care had a decline of FVC by 3.43 ml, while 
subjects in disease management program actually had an improvement of 1.32 ml.  
Propensity score is found to be significantly associated with FVC with P value of 0.0046 
(Model 2).  Propensity score adjusted model fits well as evident by decrease in AIC and 
BIC values comparing to Model 1. 
Table 14 Estimates from linear regression models for examining change in absolute  
FVC (ml) 
 Model 1 Model 2 
Fixed Effects 
 Estimates SE P value Estimates SE P value 
Intercept 2795.8 53.36 <0.0001 2690.5 63.85 <0.0001 
DMP group 723.9 161.4 <0.0001 485.3 182 0.0084 
Time -3.43 1.624 0.0360 -2.95 1.691 0.0825 
Time*DMP 4.754 3.834 0.2167 4.306 3.864 0.2668 
Propensity score    1034.5       36.02 0.0046 
Error variance 
Intercept 1134.8 79.1 <0.0001 1100.3 80.05 <0.0001 
Slope 0.1 0.045 0.0133 0.117 0.048 0.0076 
Residual 87.54 8.313 <0.0001 81.61 8.065 <0.0001 
Model Fitness 
AIC 1874.0 1707.3 




Figure 8 Longitudinal FEV1 and FVC changes in DMP Group and Usual Care Group (by 
SPIROLA software) 
 
Figure 8 is displaying longitudinal FEV1 and FVC in both the groups from 2009 
to 2013 created through CDC SPIROLA software.  Visually from the figure, there is a 
significant improvement in FEV1 among COPD subjects in disease management program 
from 2011 to 2012 and slight decline in FEV1 in third year but it is still high from 
baseline values of 2011.  But the values of FEV1 are monotonically declining from 2011 
to 2012 in usual care group.    
DMP GROUP UC GROUP 
DMP GROUP UC GROUP 
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Six minute Walk Distance (6MWD) 
 Table 15 and Table 16 presents longitudinal changes and comparison to baseline 
in six minute walk distance in meter at 0 month, 12 months and 24 months for both the 
group.  In DMP group 52 subjects have baseline 6MWD, 32 subjects have values at 12 
months and 21 subjects have values at 24 months.  There is a monotonic decline in six 
minute walk distance in DMP group from baseline to 2 years but after doing a paired t-
test analysis at 12 months and 24 months comparing values to baseline, difference is not 
statistically significant.  In usual care group distance declined slightly at 12 months but 
improved at 24 months, but doing a paired t-test analysis subjects in usual care group 
declined by 24.8 meter at 1 year and by 13.5 meter at 2 year but again the difference is 
not statistically significant. 
 
 
Table 15 Longitudinal changes in 6 MWD (meter) in DMP and Usual care group 
 0 month 12 month 24 month 
 DMP Group 
 N=52 N = 32 N = 21 
6 MWD (meter) 435.2 ± 99.1 432.3 ± 117.2 408.2 ± 134.5 
% predicted 6MWD 83.1 ± 4.5  85.7±  15.7 82.5 ±  20.2 
 Usual Care Group 
 N = 143 N = 26 N = 11 
6 MWD (meter) 318.1 ± 101.4 317 ± 90.9 347.2 ± 90.3 







Table 16 Longitudinal comparison of changes in 6 MWD 
 
Longitudinal comparison of changes in 6 MWD 
 12 month vs.  
0 month 
24 month vs.  
0 month 
DMP Group 
N 32 21 
Mean difference 
(95% CI) 
3 (-10.2, 16.2) -15.2 (-39.8, 9.5) 
P value 0.64 0.22 
Usual Care Group 
N 26 11 
Mean difference 
(95% CI) 
-24.8 (-56.3, 6.5) -13.5 (-40.9, 13.9) 




BODE index is a multidimensional grading system to evaluate COPD subjects.  
BODE index made of BMI, FEV1, mMRC dyspnea scale and six minute walk distance.  
Average BMI of subjects in disease management program at baseline was 36.1 ± 9.1, at 
12 months it was 37.2 ± 10.1 and at 24 months it was 37.9 ± 9.2.  Change in BMI was not 
statistically significant from baseline.  Figure 9 display longitudinal BODE index values 
for subjects in disease management program from baseline to 36 months.  Longitudinal 
comparison of changes in BODE index (mean difference and associated P value) is 
presented in Table 17.  At baseline average BODE index was 1.5 which was improved 
significantly at the end of 12 months with mean difference of -0.40 and P value of 0.03 
(Paired t-test).  There is also decline in BODE index at 24 months (mean difference -
0.14) but it’s not statistically significant from baseline as there are fewer subjects at 24 
months and thereafter. 
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Figure 9 Longitudinal changes in BODE index in DMP Group 
 
Table 17 Longitudinal comparison of changes in BODE index in DMP Group 
Longitudinal comparison of changes in BODE index in DMP 
group 
 12 month vs.  
0 month 
24 month vs.  
0 month 






























Cost effectiveness of the program 
 Cost analysis will be done for cost related to COPD and also cost related to major 
co-morbidities like arthritis, rhinitis, hyperlipidemia, depression, diabetes, hypertension, 
heart disease among COPD subjects in disease management program and usual care.  
Table 18 represents COPD related cost for subjects in DMP group from the time they 
first enrolled in the disease management program and this cost categorized into three 
groups (i.e. cost in first year of program, cost in second year of program and cost in third 
year of program).  From the table average cost per person per year in first year is $3693, 
which decreased to $3608.8 in second year and to $2934 in third year.  Pharmacy cost 
contributes majority of total COPD cost followed by office cost and out-patient 
hospitalization.  There are no claims for in-patient hospitalization in the third year. 
All cost related to COPD for those who are in the program is presented in Table 18 
 
Table 18 COPD related cost in DMP Group 






    
Total cost $3693.0 $3608.8 $2934.0 
Office cost $770.3 $338.5 $249.1 
In-patient cost $4.1 $191.0 $0 
Out-patient cost $223.6 $357.0 $252.5 
Home cost $28.3 $14.1 $0 
Laboratory cost $7.0 $8.4 $4.2 
Pharmacy cost $2327.0 $2591.7 $2360.2 







Table 19 represents COPD cost for DMP group and usual care group from 2009-
2013.  This cost is also average cost per person per year based on the effective and 
termination dates into health coverage.  There are total of 226 subjects in usual care 
group who claims for COPD.  Average cost per person per year for in-patient 
hospitalization is significantly high for subjects in usual care ($5578.7) versus subjects in 
DMP group ($250.9).  Pharmacy cost is high for subjects in DMP group.  Histogram of 
cost is shown in Figure 10.  Figure 11 graphically presents average cost per person per 
year for different sub-categories of COPD cost. 
Comparison of COPD related cost between two groups 
 
Table 19 Comparison of COPD related cost between two groups from 2009-2013 
 DMP Group UC Group 
Total COPD cost $2297.9 $1675.3 
     < 1 year in the program 1329.8  
     1-2 years in the program 1487.9  
     2-3 years in the program 2949.9  







Home cost $202.7 $480.6 
Laboratory cost $16.1 $53.1 
Pharmacy cost $1694.8 $496.0 
 * Values are presented in average cost per person year 
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Figure 10 Histogram of COPD related cost 
 
Figure 11-Categories of COPD cost in DMP and Usual Care Group 
 
Regression analysis results for COPD related cost from 2009-2013 were shown in 
Table 20.  Exposure time is the total time contributed into program (0 represent usual 
care, 1 means less than one year in the program, 2 means between one to two years in the 
program and 3 mean between two-three years in the program).  From table 20, subjects 
who are in program less than one year have lower COPD related cost comparing to those 
who are in usual care.  In the adjustment model propensity score is not significantly 


































Table 20 Regression model for COPD related cost 
All COPD cost Model 1 Model 2 
 Estimates P value Estimates P value 
Intercept 1675.3 0.0005 2183.1 0.0010 
Enrollment duration*     
  1 vs. 0 -345.5 0.87 -134.2 0.95 
  2 vs. 0 -187.4 0.93 -105.4 0.96 
  3 vs. 0 1274.6 0.36 1574.1 0.27 
  Propensity score   -2301.1 0.26 
 *Enrollment duration is coded as 0, 1, 2, 3; cost is presented in average cost per person per 
year; Model 2 is adjusted for propensity score 
 
Health Care Utilizations 
Table 21 summarized health care utilizations related to COPD for both the 
groups.  Subjects in disease management program have higher claims associated with 
office visits, out-patient hospitalization and laboratory testing.  Subjects in both group 
had approximately same percentage for in-patient hospitalization claims, but those in 
DMP group had significantly less number of average claims per subject (2.2 versus 12.2). 
Table 21 Health Care Utilizations and Average number of claims 
 DMP Group Usual Care 
Group 
 N=52 N=226 
≥1 IPH, n (%) 8, 15.3 34, 15.1 
Mean (SD) number of IPH 
Claims 
2.2 12.2 
≥1 OPH, n (%) 35, 67.3 112, 49.5 
Mean (SD) number of OPH 
Claims 
4.8 3.4 
≥1 Office visit, n (%) 47, 90.3 160, 70.7 
Mean (SD) number of office 
visit Claims 
15.69 4.7 
≥1 home service, n (%) 8, 15.3 25, 11.1 
Mean (SD) number of home 
service Claims 
3.8 8.9 
≥1 laboratory, n (%) 20, 38.4 50, 22.1 





Cost associated with major co-morbidities 
 As discussed in the background, COPD also imposes major economic burden 
through cost associated with major co-morbidities.  Figure 12 depicts co-morbidities 
among COPD subjects before and after enrollment in the disease management program.  
This cost was calculated as average cost per person per year.  There is a significant 
decline in cost related to all major diseases like arthritis, hypertension, hyperlipidemia, 
diabetes, and osteoporosis after enrollment of COPD subjects into disease management 
program comparing to cost before enrollment into program.   





Table 22 summarizes total healthcare cost (combining COPD related cost and 
associated morbidities), COPD related cost and cost related to major co-morbidities 
















subjects in disease management group had lower cost for arthritis, rhinitis, hypertension, 
hyperlipidemia, depression and osteoporosis. 
 
Table 22 Co-morbidities related cost in Usual Care Group and Disease management 
Group from 2009-2013 
 DMP Group 
 
Usual Care Group 
Total health care 
cost 
$18246.1 $13164.1 
COPD related cost $2297.9 $1675.3 
Asthma $1146.3 $752.2 
Arthritis $1221.8 $1790.6 
Rhinitis $120.7 $469.89 
Heart disease $9128.8 $3263.6 
Hypertension $858.0 $1007.7 
Hyperlipidemia $278.8 $435.6 
Diabetes $2399.7 $2249.9 
Depression $540.5 $1007.6 
Osteoporosis $253.6 $511.7 






 We have evaluated the effectiveness of the University of Louisville Disease 
management program for Chronic Obstructive Pulmonary disease by comparing clinical 
outcomes and cost with usual care.  Our main findings include improvement in 
respiratory measures like FEV1, FVC along with subjective measures like SGRQ.  
Implementing this chronic disease management program will reduce the impact of COPD 
on daily activities and improve overall health.  Even though subjects in disease 
management program had higher COPD related cost, cost associated with major co-
morbidities were significantly reduced for subjects in DMP group after enrollment in the 
program.   
 
Clinical effectiveness of the program 
 There are several general and respiratory measures used to assess the clinical 
effectiveness of the program and also to compare with the subjects in the usual care 
group.  PHQ9 depression scores were significantly reduced from 6.3 to 3.1 after 24 
months in the program.  Several studies
155-157
 had been done in the past to study role of 
depression among COPD cohort and found the COPD subjects with co-morbid 




confidence interval, 1.04-3.58), longer hospital stay (1.1 more days; P = .02), persistent 
smoking 2.30 (95% confidence interval, 1.17-4.52), increased symptom burden, and 
poorer physical and social functioning
155
 and also exacerbations were more frequent 
among COPD subjects with depression
157
.  Likewise general health related quality of life 
and functional health status as measured by Duke Health profile also improved from 
mean baseline value of 64.1 to 70.8 after 24 months in the disease management program.  
Thus implementing this program will significantly reduce depressive symptoms and 
comorbid outcomes associated with depression like exacerbations and longer hospital 
stay among COPD cohort. 
 Among respiratory measures, ones that are significantly improves are SGRQ, 
CAT score and BODE index.  SGRQ which is a disease specific valid instrument to 
measure the impact of COPD on health and daily life activities was improved from 37.1 
at baseline to 28.4 at 12 months (P = 0.02) and 30.2 at 24 months (P = 0.21).  Reduction 
of score by at least 4 point is considered to be clinically effective.  These findings are 
similar to study conducted by Labrecque et. al. about the role of self-management 
education program in improving quality of life
158
.  In that study subjects who were in 
intervention trial (self-management education arm) had significant improvement in 
SGRQ score at three months (mean reduction of 5 points, P = 0.006) and 12 months 
(mean reduction of 6.7, P < 0.001) in contrast to increase in score by 3.7 units in control 
group
158
.  But in that study only self-management education component was used in the 
intervention group. CAT score was also improved significantly from 18.4 to 12.2 at the 
end of one year into program and also at the end of 2 year (Figure 6).   
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 Apart from subjective measures, objective measures of pulmonary function were 
also improved significantly from baseline to 1year and 2 year (Table 10-14).  Mean FEV1 
at baseline was 2.16 liter which improved to 2.27 at the end of 1 year into program 
(P=0.0046).  FEV1 is a good predictor for mortality and thus implementing this program 
is expected to reduce the mortality among COPD subjects.  Subjects in disease 
management program had a positive longitudinal slope for FEV1 compared to subjects in 
usual care.  BODE index which is a multidimensional grading system to evaluate COPD 
subject is a good predictor of mortality among COPD subjects.  In our study BODE index 
declined by 0.40 units (95% CI: -0.78 to -0.03, P value 0.03) from baseline to 12 months 
among subjects in disease management group (Table 17).  These results are in agreement 
with the results from study by Linderman et. al.
98
 where authors studied the effect of 
proactive integrated care for COPD subjects and found that mean BODE index decreased 
by 1.1 units at the end of 12 weeks into the integrated care program.  Several previous 
studies predicted mortality among COPD subjects by longitudinally following the BODE 
index
112
.  In a longitudinal cohort study of COPD subjects by Martinez et. al., researchers 
conclude that increase in mean BODE index by more than 1 point from baseline to 6, 12, 
and 24 months of follow-up was predictive of subsequent mortality.  In our study even 
with the small number of subjects in disease management program, BODE index was 
significantly reduced at 12 months so implementing this program in a larger COPD 
cohort for a longer period of time will be expected to reduce subsequent mortality among 
COPD subjects.  In conclusion, University of Louisville COPD Disease Management 





Cost effectiveness of the program 
 Average cost related to COPD after enrollment into program in first year was 
$3693, in second year was $3608.8 and in third year it was $2934.  Average cost per 
person per year in DMP group was $2297.9 and in usual care group was $1675.3.  
Although cost related to COPD was higher among disease management subjects, there 
was significant improvement in health related quality of life of COPD subjects.  The in-
patient hospitalization cost was lower and most costs among subjects in disease 
management group were attributable to pharmaceutical expenses related to COPD 
(Figure 11).  This suggests that subjects in the disease management program were more 
adherent to their medicines and will enhance their healthy life expectancy as compared to 
those receiving usual care.  Disease management program participants also had more 
claims associated with office visits.  These findings are in agreement with the results by 
Chuang et. al. who studied the effect of patient-centric chronic obstructive pulmonary 
disease program among 141 COPD patients and found primary care physician visit were 
significantly higher among subjects in the intervention group
159
.  Patient-centric approach 
consists of initial face to face assessment by nurse, supplementation of education material 
and action plan and call from nurse staff to the subjects once every week.  The reason for 
more office visits is because subjects in disease management program have more planned 
office visits as a protocol for disease management program, but this is expected to 
improve overall quality of life and reduce the impact of COPD on daily activities and 
reduce in-patient hospitalization.  In a recent randomized control trial study of disease 
management program at different VA centers by Dewan et. al, authors found that average 
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Despite the higher cost related to COPD among subjects in the disease 
management program, costs associated with major co-morbidities were subsequently 
reduced after enrollment into disease management program (Figure 12).  Cost associated 
with heart disease and diabetes was significantly lower after enrollment into the disease 
management program.  Average cost per person per year for heart decreased from $3969 
before the enrollment to $1543 after the enrollment and for diabetes it decreased from 
$3101 to $972.  Subjects in the disease management program had significant lower cost 
for hypertension, hyperlipidemia, depression and osteoporosis comparing to subjects in 
usual care.  According to American Lung Association, indirect cost contributes 
approximately $20 billion among COPD subjects
77
, so implementing the disease 
management program is expected to significantly reduce the economic burden associated 
with COPD. 
Strengths 
 This study contributes to the growing literature on the effectiveness of disease 
management programs in chronic diseases like COPD.  We demonstrated improvement in 
absolute FEV1; previous studies showed that decreasing level of FEV1 is one significant 
predictor of mortality among COPD cohort
161
.  Implementing this chronic disease 
management program is expected to reduce the impact of COPD on daily activities and 





 There are several limitations of this study.  Certain limitations are associated with 
any retrospective record review, such as bias associated with different follow-up time for 
each group and lack of complete information on certain measures among subjects in the 
usual care group.  Secondly, the sample size in disease management group was small; 
nevertheless, we were able to detect a significant difference in FEV1 at 12 months.  Third, 
enrollment of subjects into the disease management program was not randomized and so 
there was no comparison group who had detailed and completes information on subjects 
in the same calendar time comparing to subjects in disease management program.  
Fourth, there are always limitations associated with using administrative claims data.  
The main pitfall of the claims data is that it can only identify services received for which 
a bill was submitted.  So if the charges were delayed or not submitted at all, there is 
always a chance of missing data from administrative claims database.  Also claims data 
do not provide sufficiently detailed clinical history to allow researchers to classify 
subjects based on severity of COPD.  Fifth, use of propensity score as a covariate in the 
regression analysis is not the best method we use as there are other methods like 
matching based on propensity score is an appropriate approach to control for baseline 
differences.  Finally, we were not able to identify which component of this disease 
management program works as all the subjects in the program received the full spectrum 
of interventions.  More evidence will be needed by conducting large randomized 






 Future implementation of this program at a larger scale can be recommended 
among COPD cohort and it can be randomized.  Randomization of subjects with few 
components of program in one group versus other components in second group will help 
researchers to understand exactly which component of disease management program 
works.  It may also prove worthwhile to explore a more comprehensive program for the 
simultaneous management of multiple chronic diseases (e.g. diabetes mellitus, congestive 





The University of Louisville COPD disease management program appears to be 
highly effective in improving lung health and reducing airflow limitations among COPD 
subjects as evidence by significant improvement in objective measures like FEV1.  
Program is also effective in reducing the impact of COPD on daily activities as evident 
by significant improvement in subjective measures for health related quality of life like St 
George Respiratory Questionnaire, COPD assessment test, PHQ9 and Duke Profile.  
Notwithstanding subjects in DMP had higher COPD related cost, they had significantly 
low in-patient hospitalization cost and also significant reduction in cost associated with 
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 Case Manager / Respiratory Therapist will serve as care manager to enrollees and 
liaison to physician and nurse practitioners. 
 Case Manager is embedded and working closely with physicians and mid-level 
health care providers. 
 Primary care physicians will be advised of program and provided clinical updates 
of enrollees. 
 High amount of personal touch and face-to-face time with program participants. 
Program Components: 
I. COPD Screening: 
 Potential enrollees will be targeted and recruited into the program as outlined 
above. 
 
II. Participant requirements: 
 The program will be explained and the potential enrollee will be required to 
sign a participation agreement documenting their intention to participate fully 
in the program. 
III.a Each enrollee will have an initial Comprehensive Evaluation and Assessment, 
which will include: 
 Performed at Healthcare Outpatient Center by ULP 
 Comprehensive Office visit 
 6 Minute Walk Test 
 Pulmonary Function Testing, complete, with and without bronchodilator 
 Fractional exhaled nitric oxide 
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 Overnight oximetry 
 ECG 
 Alpha-1 anti-trypsin level (we use a HIPAA certified laboratory that provides 
this service at no charge) 
 Questionnaires (PHQ9, St. George Respiratory Questionnaire, Epworth 
Sleepiness Score, Duke Profile) 
 Performed at HealthCare Outpatient Center by ULH 
 Chest X-Ray (if not done within the past 12 months) 
 Sputum Analysis  (if enrollee fits into category of chronic bronchitis with 
sputum production) 
III.b Follow-up Visits 
 Follow-up visits and testing is based on disease risk stratification.  In general, 
those with mild COPD, as determined by GOLD stages 1-2, are followed less 
often and less intensely.  Those with more severe COPD, as determined by 
GOLD stages 3-4, are followed more closely.  See below. 
COPD GOLD STAGES 1 or 2 
 6 month follow-up clinic visits 
 Spirometry  
 Review Action Plan 
 Questionnaire (PHQ9, Duke Profile, Respiratory Health) 
  COPD GOLD STAGE 3 or 4 




 Review Action Plan 
 6 minute walk test (every 6 months) 
 Questionnaire (PHQ9, Duke Profile, Respiratory Health) 
IV. Support Group Education Classes 
 All participants will be required to participate in a group education session 
which covers a variety of topics including COPD causes and prevention, 
nutrition, exercise, healthy life style, bone health, proper medication use, 
tobacco cessation and self-management of their disease.  These classes are 
held monthly and are run by our certified respiratory therapists with support 
from our pulmonologists and nurse specialists. 
 Additionally, individualized education and training is provided by the clinic 
respiratory therapists and these concepts are reinforced with most every 










Variable Points on BODE index 
 0 1 2 3 
BMI >21 ≤21   
FEV1 ≥65 50-64 36-49 ≤35 
MMRC dyspnea scale 0-1 2 3 4 
Distance walked in 6 
minutes 
≥350 250-349 150-249 ≤149 
































































 A doctorate degree in epidemiology with special interest in epidemiological 
research, health economics and outcome research, pharmacoepidemiology, 
research methodology, comparative effectiveness research 
 Strong background in epidemiology and biostatistics 
 Trained in advanced statistical methods including Hierarchical Linear Modeling 
and propensity score analysis 
 2 years of experience in analyzing administrative claims data 
 More than 5 years of experience in SAS 





Doctor of Philosophy (Ph.D.) 
Aug 2010 – April 2014  
Concentration: Epidemiology with minor in Biostatistics  
University of Louisville, Louisville, Kentucky 
Dissertation: Clinical and Cost Effectiveness of Chronic Obstructive Pulmonary Disease 
management program at the University of Louisville 
Committee: Dr. Frank Groves (chair), Dr. Rodney Folz (advisor), Dr. Richard 
Baumgartner, Dr. Susan Muldoon, Dr. Guy Brock 
 
Master of Public Health (M.P.H.) 
Aug 2005-May 2009 
Concentration: Epidemiology with minor in Biostatistics 
University of Kentucky, Lexington, KY 
Thesis: Comparison of 3 versus 4 and Protease Inhibitors (PI) versus non-PI 





Committee: Dr. Steven Browning (chair), Dr. Richard Greenberg (advisor), Dr. Heather 
Bush 
Bachelor of Medicine and Bachelor of Surgery (equivalent to MD) 
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Graduate Research Assistant August 2012-present 
Department of Epidemiology, University of Louisville 
Supervisor: Dr. Frank Groves, Dr. Rodney Folz 
 
- Analyzed administrative claims data from United Healthcare retrospectively 
- Prepared and submitted IRB documents 
- Retrieved data from Electronic Medical Records 
- Assisted supervisors in writing grant proposal 
- Reviewed literature for research proposal 
 
Graduate Fellow August 2010-July2012 
Department of Epidemiology, University of Louisville 
Supervisor: Dr. Richard Baumgartner 
 
- Analyzed large data sets like NHANES, NHEFS using advanced statistical 
methods like logistic regression, linear regression, survival analysis 
- Prepared manuscript for submission to peer review journals 
 
Research Associate July 2008-April 2010 
University of Kentucky 
Supervisor: Dr. Juan Yepes 
   
- Developed proposals under supervision of Principal Investigator 
- Analyzed data from randomized controlled trial of Burning mouth disorder 
and dry mouth 
- Assisted supervisor in grant writing, preparing IRB documents, recruiting 
subjects for trial and collected primary data. 
- Prepared manuscript for peer review journal submission 
- Provided Quality Assurance of analytic file 
- Performed project related statistical analysis & interpreted results 




Research Assistant Aug 2006- June 2008 
University of Kentucky 




- Assisted supervisor in IRB submission and literature review 





 Ordinary Least Square regression  
 General Linear Modeling 
 Survey design adjusted multivariate analysis 
 Longitudinal Data Analysis 
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Poster presented at Annual Meeting of Hispanic Dental Association; Carefree, AZ 
(Nov 2008) 
 
 Anand G. Vaishnav, Creed Pettigrew, Michael Dobbs, Stephan Ryan, Malhar 
Jhaveri, Lisa Bellamy.  JCAHO Primary Stroke Center Core Measures: Influence 
of Stroke Care Unit 
Poster presented at American Academy of Neurology; Chicago, IL (May 2008) 
 
 Kiyoung Lee, Elien Hahn, Malhar Jhaveri, Riker, R, Sara Head.  Indoor Air 
Quality and Enforcement of Smoke-free Policies in public venues and schools 
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Poster presented at International Conference on Environmental Epidemiology; 







 Malhar Jhaveri, Heather Bush, Steven Browning, Alice Thornton, Richard 
Greenberg.  Comparison of 3 versus 4 Drugs as Initial HAART: University of 
Kentucky Experience from 1998-2007 
Presented at American Federal Medical Research Southern Regional Conference; 
New Orleans, LA (Feb 2009) 
 
 
HONORS/AWARDS AND ACTIVITIES: 
 
 First Place Doctoral student award at Research Louisville conference (Sep 2013) 
 
 Inducted into the University of Kentucky Delta Epsilon Iota society (Jan 2008) 
 
 Student Facilitator in a "22nd Kentucky Governors Safety and Health 
Conference", Louisville, KY (May 2006) 
 
 Certificate for excellent work on Tobacco Cessation Clinic, WHO conducted 
Pulse Polio Immunization program and Ministry of Health and Family Welfare 
(Jul 2004). 
